BioNTech reports rapid progress on COVID-19 vaccine program to address global public health threat

Announces BNT162 vaccine program for the prevention of COVID-19 infection

Anticipates start of clinical testing for vaccine in late April 2020

Plans to assemble a global consortium of partners to address the pandemicA A 

MAINZ, Germany, March 16, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, a??BioNTecha?? or a??the Companya??) provides further details today on the Companya??s R&D effort, a??Project Lightspeeda??, to develop a potential vaccine to induce immunity and prevent COVID-19 infection in response to the growing global health threat posed by the disease. BioNTecha??s product candidate, BNT162, is a potential first-in-class mRNA vaccine in the worldwide effort against COVID-19.BioNTech intends to initiate clinical testing for BNT162 in late April 2020, subject to regulatory approval, as part of a global clinical development program in Europe (commencing in Germany), the United States and China. The Company has been in close contact with regulatory and scientific authorities around the world and is in ongoing discussions with other pharmaceutical companies and research bodies to make a vaccine available to the public as quickly as possible worldwide.As part of its global development program, BioNTech announced today a strategic alliance with Fosun Pharma to jointly develop its COVID-19 vaccine in China. In addition, BioNTech is in advanced discussions with its existing collaborator Pfizer regarding the development of the vaccine outside China. BioNTech plans to manufacture the vaccine for clinical trials along with its partner Polymun at BioNTecha??s state-of-the-art GMP certified mRNA manufacturing facilities in Europe, and is preparing to ramp up production for global supply in collaboration with its partners.a??We feel a duty to exploit our full technology and immunotherapy expertise to help address the COVID-19 pandemic emergency. We are working closely together with regulatory agencies and our existing collaborators in the infectious disease field, including Pfizer, to rapidly initiate trials in order to make a vaccine available to the public as quickly as possible worldwide. In addition, we are working on a novel therapeutics approach for those patients who have already been infected a?? we plan to disclose more on that effort in the coming weeks,a?? says Founder and CEO of BioNTech, Ugur Sahin, M.D. About BNT162
BNT162 is BioNTecha??s mRNA vaccine program aimed at preventing COVID-19 infection and is the first product candidate from Project Lightspeed. Lightspeed is BioNTecha??s accelerated development program encompassing the prevention and treatment of COVID-19 infection, which leverages BioNTecha??s proprietary mRNA platforms for infectious diseases, its fully-owned GMP manufacturing infrastructure for mRNA vaccine production and its global clinical development capabilities, drawing on BioNTecha??s broad network of global collaborators.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Октябрь 2020    »